Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from AdAlta Ltd. ( (AU:1AD) ).
AdAlta Ltd. announced the application for quotation of 1,396,999 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move is part of the company’s strategy to enhance its capital structure and support its ongoing development projects, potentially strengthening its market position and offering new opportunities for stakeholders.
The most recent analyst rating on (AU:1AD) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on AdAlta Ltd. stock, see the AU:1AD Stock Forecast page.
More about AdAlta Ltd.
AdAlta Ltd. operates in the biotechnology industry, focusing on the development of innovative therapies using its proprietary i-body technology. The company aims to address unmet medical needs in various markets, leveraging its expertise in biologics.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$6.62M
For a thorough assessment of 1AD stock, go to TipRanks’ Stock Analysis page.